Serum ESPL1 levels showed an increasing trend across the CHB, LC, and HBV-HCC groups, with levels at 224.6 ng/L, 285.8 ng/L, and 440.4 ng/L respectively. This evidence concerns the gene ESPL1 and hepatocellular carcinoma.